Gilead Sciences Files 8-K on Financials
Ticker: GILD · Form: 8-K · Filed: Apr 25, 2024 · CIK: 882095
| Field | Detail |
|---|---|
| Company | Gilead Sciences, INC. (GILD) |
| Form Type | 8-K |
| Filed Date | Apr 25, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: GILD
TL;DR
Gilead dropped an 8-K on April 25th about their financials - check it for the latest numbers.
AI Summary
Gilead Sciences, Inc. filed an 8-K on April 25, 2024, reporting on its results of operations and financial condition, as well as filing financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but serves as a notification of these items.
Why It Matters
This filing indicates that Gilead Sciences is providing updates on its financial performance and condition to the SEC, which is important for investors to stay informed about the company's health.
Risk Assessment
Risk Level: low — The filing is a standard disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- GILEAD SCIENCES, INC. (company) — Registrant
- April 25, 2024 (date) — Date of Report
- 333 Lakeside Drive, Foster City, California 94404 (address) — Principal executive offices
FAQ
What specific financial results or conditions are being reported by Gilead Sciences in this 8-K?
The provided text of the 8-K filing does not contain specific details on the financial results or conditions being reported, only that these items are being disclosed.
When was this 8-K filing submitted to the SEC?
The filing was submitted on April 25, 2024.
What is the primary purpose of this 8-K filing for Gilead Sciences?
The primary purpose is to report on the company's Results of Operations and Financial Condition, and to file Financial Statements and Exhibits.
Where are Gilead Sciences' principal executive offices located?
Gilead Sciences' principal executive offices are located at 333 Lakeside Drive, Foster City, California 94404.
What is the SEC file number for Gilead Sciences?
The SEC file number for Gilead Sciences is 000-19731.
Filing Stats: 682 words · 3 min read · ~2 pages · Grade level 11.3 · Accepted 2024-04-25 16:04:55
Key Financial Figures
- $0.001 — ch registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select
Filing Documents
- gild-20240425.htm (8-K) — 32KB
- exhibit991earningspressrel.htm (EX-99.1) — 469KB
- gilead_transparentxlogoxst.jpg (GRAPHIC) — 36KB
- 0000882095-24-000010.txt ( ) — 703KB
- gild-20240425.xsd (EX-101.SCH) — 2KB
- gild-20240425_lab.xml (EX-101.LAB) — 21KB
- gild-20240425_pre.xml (EX-101.PRE) — 12KB
- gild-20240425_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On April 25, 2024 , Gilead Sciences, Inc., a Delaware corporation ("Gilead"), issued a press release announcing its financial results for the quarter ended March 31, 2024. A copy of the press release is filed as Exhibit 99.1 to this report. Gilead has presented certain financial information in accordance with U.S. generally accepted accounting principles ("GAAP") and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead's GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead's operating results as reported under GAAP. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 9, 10 and 11 of the press release filed as Exhibit 99.1 to this report. The information in Item 2.02 and Item 9.01 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing. Section 9 - FINANCIAL STATEMENTS AND EXHIBITS
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, issued by Gilead Sciences, Inc. on April 25, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GILEAD SCIENCES, INC. (Registrant) /s/ ANDREW D. DICKINSON Andrew D. Dickinson Chief Financial Officer Date: April 25, 2024 Exhibit Index Exhibit Number Description 99.1 Press Release, issued by Gilead Sciences, Inc. on April 25, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)